PRAGMMATIC
A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma
What will happen during the trial?
PRIMARY OBJECTIVE:
I. Compare the overall survival between bortezomib, lenalidomide and dexamethasone (VRd), daratumumab, lenalidomide and dexamethasone (DRd) and daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) used as initial therapy for patients with newly diagnosed MM.
OUTLINE: This is an observational study.
Patients have their medical records reviewed on study.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Observational Trial
- Enrollment
- 2,370 patients (estimated)
- Sponsors
- Mayo Clinic
- Trial Type
- Observational
- Last Update
- 2 weeks ago
- SparkCures ID
- 1818
- NCT Identifier
- NCT06151717
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.